Evidence map›Paper›PMID 42136725›Full record

ReviewFrontiers in cardiovascular medicine2026

Artificial intelligence in cardio-oncology: decoding mechanisms, predicting toxicity, and personalizing cancer therapy.

Chengqi Yu, Leilei Jiang, Liuhua Long, Huiming Yu

Abstract readReview
In one paragraph

Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Chengqi YuNational Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Leilei JiangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
Liuhua LongKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
Huiming YuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer therapy-related cardiovascular toxicity (CTR-CVT) threatens the sustainability of oncological advancements, demanding innovative approaches for early risk stratification. This review synthesizes how artificial intelligence (AI) is redefining cardio-oncology through multimodal integration of multi-omics, dynamic imaging, and real-world biosensor data. By decoding novel pathophysiological mechanisms and enabling continuous risk reclassification, AI transcends traditional static paradigms to generate patient-specific toxicity trajectories. Crucially, AI-driven interventions shift clinical practice from reactive monitoring to preemptive cardioprotection. While challenges in data heterogeneity, model interpretability, and equitable implementation persist, emerging solutions like federated learning and explainable AI pave the way for robust clinical translation. We hope that this review will summarize the current state of emerging applications of machine learning and AI in precision medicine predictive modeling, providing direction for AI-enabled precision cardiovascular oncology-ensuring the effectiveness of cancer treatment while safeguarding long-term cardiovascular health through personalized risk mitigation measures.

Indexed as

artificial intelligencecancer survivorshipcardio-oncologycardiotoxicityprecision medicinerisk prediction

Identifiers

PMID42136725
PMCPMC13167503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.